problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201056347-51problendo-4763Research ArticleСтатьиArticles'Метаболически здоровые' лица с ожирением и метаболические признаки ожирения у лиц с нормальной массой тела: что за этим стоит?Metabolically healthy obese subjects and metabolic signs of obesity in subjects with normal body weight: what is behind?BershteĭnL Mlevmb@endocrin.spb.ruKovalenkoI G-201015062010563ТОМ 56, №3 (2010)4751Copyright © Bershteĭn L.M., Kovalenko I.G., 20102010Bershteĭn L.M., Kovalenko I.G.Bershteĭn L.M., Kovalenko I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4763

В обзоре обсуждается современное представление о гетерогенности ожирения, позволяющее, в частности, выделить группу людей с ожирением без метаболических нарушений (metabolically healthy obese, MHO) и, наоборот, группу лиц с нормальной массой тела и признаками гормонально-метаболических нарушений (metabolically obese normal weight, MONW). Особая подгруппа представлена пациентами с так называемым ожирением с дефицитом мышечной массы или силы (sarcopenic obesity). Рассматриваются потенциальные механизмы возникновения этих состояний и некоторые прикладные аспекты данной проблемы.

The current concept of obesity as a heterogeneous condition is discussed. Such interpretation provides a basis for distinguishing a group of obese subjects without metabolic disturbances (metabolically healthy obese (MHO) subjects) and another one including subjects with normal body weight and signs of hormonal and metabolic disorders (metabolically obese normal weight (MONW) subjects). A separate subgroup is represented by obese patients with deficit of muscular mass and force (sarcopenic obesity). Potential mechanisms underlying development of these conditions are considered along with selected applied aspects of this problem.

ожирениемасса и композиционный состав телажировая и мышечная тканьинсулинорезистентностьobesitybody weight and compositionadipose and muscular tissueinsulin resistanceReferencesБерштейн Л.М. Гормоны жировой ткани (адипоцитокины): онтогенетический и онкологический аспект проблемы. Успехи геронтол 2005;16:1:51-64.Берштейн Л.М. Гормоны жировой ткани (адипоцитокины): онтогенетический и онкологический аспект проблемы. Успехи геронтол 2005;16:1:51-64.Берштейн Л.М. Рак гормонозависимых тканей в системе основных неинфекционных заболеваний человека. Ст-Петербург: Эскулап 2009;180.Берштейн Л.М. Рак гормонозависимых тканей в системе основных неинфекционных заболеваний человека. Ст-Петербург: Эскулап 2009;180.Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. Рос мед журн 2001;9:2:56-62.Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. Рос мед журн 2001;9:2:56-62.Дедов И.И., Мельниченко Г.А. (ред.) Ожирение. М: МИА 2004;456.Дедов И.И., Мельниченко Г.А. (ред.) Ожирение. М: МИА 2004;456.Квачевская Ю.О. Особенности рака эндометрия при синдроме инсулинорезистентности: Автореф. дис. ... канд. мед. наук. Ст-Петербург 2000;25.Квачевская Ю.О. Особенности рака эндометрия при синдроме инсулинорезистентности: Автореф. дис. ... канд. мед. наук. Ст-Петербург 2000;25.Косыгина А.В., Васюкова О.В. Жировая ткань и роль адипоцитокинов. Пробл эндокринол 2009;1:44-50.Косыгина А.В., Васюкова О.В. Жировая ткань и роль адипоцитокинов. Пробл эндокринол 2009;1:44-50.Романцова Т.И. Патогенетический подход к лечению ожирения и сахарного диабета 2-го типа. Ожирение и метаболизм 2008;4:17:2-10.Романцова Т.И. Патогенетический подход к лечению ожирения и сахарного диабета 2-го типа. Ожирение и метаболизм 2008;4:17:2-10.Adult Treatment Panel III final report. Circulation 2002;106: 10:3143-3421.Adult Treatment Panel III final report. Circulation 2002;106: 10:3143-3421.Aguilar-Salinas C.A., García E.G., Robles L. et al. High Adiponectin Concentrations Are Associated with the Metabolically Healthy Obese Phenotype. J Clin Endocrinol Metab 2008;93:10:4075-4079.Aguilar-Salinas C.A., García E.G., Robles L. et al. High Adiponectin Concentrations Are Associated with the Metabolically Healthy Obese Phenotype. J Clin Endocrinol Metab 2008;93:10:4075-4079.Allan C.A., Strauss B.J., McLachlan R.I. Body composition, metabolic syndrome and testosterone in ageing men. Int J Impot Res 2007;19:448-457.Allan C.A., Strauss B.J., McLachlan R.I. Body composition, metabolic syndrome and testosterone in ageing men. Int J Impot Res 2007;19:448-457.Andres R. Effect of obesity on total mortality. Int J Obstet 1980;4:4:381-386.Andres R. Effect of obesity on total mortality. Int J Obstet 1980;4:4:381-386.Barter P., McPherson Y.R., Song K. et al. Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. J Clin Endocrinol Metab 2007;92:6:2041-2045.Barter P., McPherson Y.R., Song K. et al. Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. J Clin Endocrinol Metab 2007;92:6:2041-2045.Baumgartner R.N. Body composition in healthy aging. Ann NY Acad Sci 2000;904:437-448.Baumgartner R.N. Body composition in healthy aging. Ann NY Acad Sci 2000;904:437-448.Brochu M., Tchernof A., Dionne I.J. et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001;86:4:1020-1025.Brochu M., Tchernof A., Dionne I.J. et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001;86:4:1020-1025.Chan J.C., Malik V., Jia W. et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:20:2129-2140.Chan J.C., Malik V., Jia W. et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:20:2129-2140.De Lorenzo A., Del Gobbo V., Premrov M. G. et al. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr 2007;85:1:40-45.De Lorenzo A., Del Gobbo V., Premrov M. G. et al. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr 2007;85:1:40-45.Drolet R., Richard C., Sniderman A.D. et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obset (Lond) 2008;32:2:283-291.Drolet R., Richard C., Sniderman A.D. et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obset (Lond) 2008;32:2:283-291.Dvorak R.V., DeNino W.F., Ades P.A., Poehlman E.T. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes 1999;48:5:2210-2214.Dvorak R.V., DeNino W.F., Ades P.A., Poehlman E.T. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes 1999;48:5:2210-2214.Goodpaster B.H., Park S.W., Harris T.B. et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol (A) Biol Sci Med Sci 2006;61A:5:1059-1064.Goodpaster B.H., Park S.W., Harris T.B. et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol (A) Biol Sci Med Sci 2006;61A:5:1059-1064.Hittel D.S., Berggren J.R., Shearer J. et al. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009;58:1:30-38.Hittel D.S., Berggren J.R., Shearer J. et al. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009;58:1:30-38.Janssen I. Heart disease risk among metabolically healthy obese men and metabolically unhealthy lean men. Can Med Ass J 2005;172:10:1315-1316.Janssen I. Heart disease risk among metabolically healthy obese men and metabolically unhealthy lean men. Can Med Ass J 2005;172:10:1315-1316.Karelis А. Metabolically healthy but obese individuals. Lancet 2008;372 :9646 :1281-1283.Karelis А. Metabolically healthy but obese individuals. Lancet 2008;372 :9646 :1281-1283.Karelis A.D., Brochu M., Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab 2004;30:3:569-572.Karelis A.D., Brochu M., Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab 2004;30:3:569-572.Karelis A.D., Faraj M., Bastard J.P. et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005;90:7:4145-4150.Karelis A.D., Faraj M., Bastard J.P. et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005;90:7:4145-4150.Karelis A.D., Fontaine J., Rabasa-Lhoret R. et al. Psychosocial profile of the metabolically healthy but obese postmenopausal woman. Diabetes Metabolism 2006;32:1:90-91.Karelis A.D., Fontaine J., Rabasa-Lhoret R. et al. Psychosocial profile of the metabolically healthy but obese postmenopausal woman. Diabetes Metabolism 2006;32:1:90-91.Karelis A.D., St-Pierre D.H., Conus F. et al. Metabolic and body composition factors in subgroups of obesity. J Clin Endocrinol Metab 2004;89:8:2569-2575.Karelis A.D., St-Pierre D.H., Conus F. et al. Metabolic and body composition factors in subgroups of obesity. J Clin Endocrinol Metab 2004;89:8:2569-2575.Katzmarzyk P.T., Church T.S., Janssen I. et al. Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Diabetes Care 2005;28:2:391-397.Katzmarzyk P.T., Church T.S., Janssen I. et al. Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Diabetes Care 2005;28:2:391-397.Lauretani F., Russo C., Bandinelli S. et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003;95:1851-1860.Lauretani F., Russo C., Bandinelli S. et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003;95:1851-1860.Lynch L., O' Connell1 J., Kwasnik A. et al. Metabolically unhealthy obese patients have decreased and altered circulating natural killer cells and increased adipocyte size compared to obese metabolically healthy patients. Endocrine Abstracts 2008;15:1:139.Lynch L., O' Connell1 J., Kwasnik A. et al. Metabolically unhealthy obese patients have decreased and altered circulating natural killer cells and increased adipocyte size compared to obese metabolically healthy patients. Endocrine Abstracts 2008;15:1:139.Marini M.A., Succurro E., Frontoni S. et al. Metabolically Healthy but Obese Women Have an Intermediate Cardiovascular Risk Profile Between Healthy Nonobese Women and Obese Insulin-Resistant Women. Diabetes Care 2007;30:8:2145-2147.Marini M.A., Succurro E., Frontoni S. et al. Metabolically Healthy but Obese Women Have an Intermediate Cardiovascular Risk Profile Between Healthy Nonobese Women and Obese Insulin-Resistant Women. Diabetes Care 2007;30:8:2145-2147.Oflaz H., Ozbey N., Mantar F. et al. Determination of endothelial function and early atherosclerotic changes in healthy obese women. Diabet Nutr Metab 2003;16:1:176-181.Oflaz H., Ozbey N., Mantar F. et al. Determination of endothelial function and early atherosclerotic changes in healthy obese women. Diabet Nutr Metab 2003;16:1:176-181.Prado C.M., Lieffers J.R., McCargar L.J. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:7:629-635.Prado C.M., Lieffers J.R., McCargar L.J. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:7:629-635.Ruderman N., Chisholm D., Pi-Sunyer X., Schneider S. The metabolically-obese, normal weight individual revisited. Diabetes 1998;47:5:699-713.Ruderman N., Chisholm D., Pi-Sunyer X., Schneider S. The metabolically-obese, normal weight individual revisited. Diabetes 1998;47:5:699-713.Ruderman N., Schneider S., Berchtold P. The «metabolically-obese», normal-weight individual. Am J Clin Nutr 1981;34:5:1617-1621.Ruderman N., Schneider S., Berchtold P. The «metabolically-obese», normal-weight individual. Am J Clin Nutr 1981;34:5:1617-1621.Rodeheffer M.S., Birsoy K., Friedman J.M. Identification of white adipocyte progenitor cells in vivo. Cell 2008;135:2:240-249.Rodeheffer M.S., Birsoy K., Friedman J.M. Identification of white adipocyte progenitor cells in vivo. Cell 2008;135:2:240-249.Sims E.A. Are there persons who are obese, but metabolically healthy? Metabolism 2001;50:7:1499-1504.Sims E.A. Are there persons who are obese, but metabolically healthy? Metabolism 2001;50:7:1499-1504.Stenholm S., Harris T.B., Rantanen T. et al. Sarcopenic obesity: definition and etiology. Curr Opin Clin Nutr Metab Care 2008;11:6:693-700.Stenholm S., Harris T.B., Rantanen T. et al. Sarcopenic obesity: definition and etiology. Curr Opin Clin Nutr Metab Care 2008;11:6:693-700.St-Onge M.P., Janssen I., Heymsfield S.B. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 2004;27:9:2222-2228.St-Onge M.P., Janssen I., Heymsfield S.B. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 2004;27:9:2222-2228.St-Pierre A.C., Cantin B., Mauriège P. et al. Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. Can Med Ass J 2005;172 :10 :1301-1305.St-Pierre A.C., Cantin B., Mauriège P. et al. Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. Can Med Ass J 2005;172 :10 :1301-1305.

The authors declare that there are no conflicts of interest present.